Introduction {#S0001}
============

Since the first antibiotic penicillin was discovered in the 1940s, illnesses and deaths from infectious diseases have remarkably reduced.[@CIT0001] However, the war between pathogens and antibiotics continues because pathogens gradually adapt to their external environment, including various antibiotics. Misuse or widespread use of antibiotics accelerates antibiotic resistance, which is one of the most serious health threats.[@CIT0002],[@CIT0003] The appearance of methicillin-resistant *Staphylococcus aureus* (MRSA), carbapenem-resistant *Enterobacteriaceae* (CRE), vancomycin-resistant *Enterococcus*, and other drug-resistant pathogens has not only compromised the treatment of infectious diseases but also undermined many achievements from different health fields.[@CIT0002] The widespread of antibiotic resistance is found among 500,000 people with suspected bacterial infections from 22 countries by the WHO's Global Antimicrobial Surveillance System (GLASS).[@CIT0003] In the United States, more than 2 million people were infected with drug-resistant pathogens, causing the death of at least 23,000 people annually.[@CIT0002] Similarly, antibiotic resistance has been a considerable burden on People's Republic of China,[@CIT0004],[@CIT0005] given that the ration of MRSA, extended-spectrum β-lactamase (ESBL)-producing *Enterobacteriaceae*, and carbapenem-resistant *Acinetobacter baumannii* was over 50% of the corresponding isolates nationwide in 2009.[@CIT0005]

The way antibiotics are used needs to be changed, as it may be the single most important strategy to effectively slowdown the spread and development of antibiotic resistance.[@CIT0002],[@CIT0006] For instance, polymyxin B was rarely used clinically for decades due to its toxicity.[@CIT0007] However, it has been gradually employed as a first-line agent against extensively drug-resistant pathogens because of its consistently high sensitivity rate.[@CIT0008] WHO and Centers for Disease Control and Prevention of the United States have managed several programs, such as GLASS[@CIT0001] and Get Smart program,[@CIT0006] to address antimicrobial resistance, emphasizing the importance of appropriate antibiotic usage and surveillance of antibiotic resistance. The Chinese Ministry of Health also launched the national antibiotic stewardship program, People's Republic of China antimicrobial resistance surveillance system, and other policies to control antibiotic resistance.[@CIT0005],[@CIT0009],[@CIT0010] Based on this background, the First Affiliated Hospital of Zhejiang University (FAHZU), ranking one of the first-class hospitals in People's Republic of China, has implemented multifaceted interventions, including pharmacist-led antibiotic stewardship, surveillance and regular proclamation of antibiotic resistance data, financial penalties, and so on. Although the antibiotic consumption and resistance in People's Republic of China were characterized in previous studies,[@CIT0004],[@CIT0011]--[@CIT0016] few studies focused on the correlation between these two elements during a relatively long period. Furthermore, several important pathogens, such as *Enterococcus faecalis* and *Enterococcus faecium*, were seldom reported. Therefore, this study described the improvements and shortcomings of drug resistance status and provided an overview on the trends and correlation between the antibiotic consumption and sensitivity rates in FAHZU from 2007 to 2016.

Methods {#S0002}
=======

Setting and study design {#S0002-S2001}
------------------------

This observational and retrospective study was based on the yearly data of antibiotic susceptibility and consumption in FAHZU from 2007 to 2016. Located in the east of People's Republic of China, FAHZU is a 2500-bed capacity tertiary-care teaching hospital founded in 1947. It is now ranked as the top 10 medical facility in People's Republic of China and has been the best hospital in Zhejiang Province.

Antimicrobial stewardships in the FAHZU {#S0002-S2002}
---------------------------------------

From 2007 to 2016, the FAHZU implemented multifaceted interventions to combat antibiotic resistance, mainly including: 1) surveillance and regular proclamation of antibiotic resistance data and proportion of patient receiving antibiotic prescriptions; 2) structured antibiotic use policy;. a structured antibiotic use policy ([Table S1](http://www.dovepress.com/get_supplementary_file.php?f=210872.docx)) has been established in FAHZU to improve the usage of antibiotics. According to this policy, antibiotics were classified as nonrestricted, restricted, and very-restricted types on the basis of their safety, efficacy, resistance rate, and cost. The prescribing requirements were also different for each type; 3) the infectious disease department in the FAHZU kept collaboration with physicians and pharmacists to improve the practice in health care workers; 4) pharmacist-led antibiotic stewardship, including prescription evaluation program, consultation for very-restricted antibiotics, and therapeutic drug monitoring for a series of antibiotics; 5) financial penalties and point-based system that prescribing privileges are revoked if the cumulative score is 12 points; 6) regular Plan--Do--Check--Action programs involving improvement of the rationality to use prophylactic antibiotics in surgical site infection and intervention procedure;[@CIT0017] 7) education programs.

Bacterial identification and antibiotic susceptibility tests {#S0002-S2003}
------------------------------------------------------------

Data on pathogens isolated from patients admitted to the hospital were retrospectively obtained from FAHZU. The isolates were identified by the VITEK 2 compact system (bioMérieux), and antibiotic susceptibility was determined by either the disc diffusion method[@CIT0018] or the VITEK 2 compact system. The results were then interpreted uniformly in accordance with the Clinical and Laboratory Standards Institute criteria.[@CIT0018] To guarantee the reproducibility of testing methodologies, we used *E. faecalis* ATCC 29212, *S. aureus* ATCC 25923, *Pseudomonas aeruginosa* ATCC 27853, and *Escherichia coli* ATCC 25922 as reference strains.

The pathogens included in this study were *Klebsiella pneumoniae, E. coli, A. baumannii, P. aeruginosa, S. aureus*, coagulase-negative *Staphylococcus* (CNS), *E. faecalis*, and *E. faecium*, which were the most frequent isolates in our hospital for the past 10 years. The isolation density for each species was the number of isolates per 10,000 patient-days (10,000-pd). The susceptibility rate of each antibiotic was calculated as the number of susceptible isolates divided by the total isolation number.

Antibiotic consumption {#S0002-S2004}
----------------------

The data of antibiotic consumption from 2007 to 2016 were obtained from the database of the Pharmacy Department. Antibiotic consumption[@CIT0019] in this study was measured based on the number of defined daily dose (DDD) normalized per 1000-pd. The DDD is the assumed average maintenance dose per day of the corresponding antibiotic used for its main indication in adults and was obtained from the ATC/DDD Index 2018.[@CIT0019]

Statistical analyses {#S0002-S2005}
--------------------

Trends of isolation density, antibiotic consumption, and susceptibility were determined by linear regression. Pearson's correlation coefficient was calculated to identify the relationship between antibiotic consumption and susceptibility. Statistical significance was considered at *p*\<0.05, and IBM SPSS Statistics (version 23) was used for all the analyses.

Results {#S0003}
=======

Bacterial isolates {#S0003-S2001}
------------------

Of the 732.5/10,000-pd isolates, 14.91% was *E. coli*, 10.16% was *K. pneumoniae*, 11.15% was *A. baumannii*, and 9.21% was *P. aeruginosa*. The most frequently isolated Gram-positive pathogens were CNS (16.80%), *S. aureus* (5.49%), *E. faecium* (4.08%), and *E. faecalis* (3.89%). All of them accounted for 75.70% of the isolated pathogens during the study period.

Antimicrobial susceptibility {#S0003-S2002}
----------------------------

As shown in [Figure 1](#F0001){ref-type="fig"}, susceptibility to many antibiotics increased markedly in different pathogens from 2007 to 2016. Consistent with the overall variation, the susceptibility to majority of the antibiotics rose remarkably in *E. coli*. In addition, the proportion of ESBL-producing isolates significantly decreased in *E. coli* (r=−0.745, *p*=0.013, [Figure 1A](#F0001){ref-type="fig"}) and *K. pneumoniae* (r=−0.789, *p*=0.007, [Figure 1A](#F0001){ref-type="fig"}). However, the susceptibility to imipenem and cefoperazone/sulbactam decreased in *K. pneumoniae* during the surveillance period. The susceptibility to ciprofloxacin (r=0.713, *p*=0.031) and amikacin (r=0.749, *p*=0.013) in *A. baumannii* has improved remarkably during the past 10 years. Whereas its susceptibility to cefoperazone/sulbactam, which is an important option for infections caused by *A. baumannii* ([Figure 1A](#F0001){ref-type="fig"} and [C](#F0001){ref-type="fig"}), decreased significantly from 59% in 2007 to 28% in 2016 (r=−0.783, *p*=0.007).Figure 1Trends of antibiotic susceptibility in FAHZU, 2007--2016.**Notes:** Rates of important Gram-negative pathogens (**A**) and Gram-positive pathogens (**B**). The susceptibility of Gram-negative pathogens (**C:** a and b) and Gram-positive pathogens (**C:** d and e), and the trends of susceptibility from 2007 to 2016 (**C:** c and f). ^1,2,4^The study period of susceptibility: aztreonam and SXT (2008--2016), cefazolin (2010--2016), piperacillin／tazobactam in *A. baumannii* (2007--2015), ciprofloxacin in *A. baumannii* (2008--2016). ^3^Gentamicin with a high concentration.**Abbreviations:** S, sensitive; eco, *E. coli*; kpn, *K. pneumoniae*; aba, *A. baumannii*; pae, *P. aeruginos*; sau, *S. aureus*; CNS, coagulase-negative *Staphylococcus*; efm, *E. faecium*; efa, *E. faecalis*; SCF, cefoperazone/sulbactam; TZP, piperacillin/tazobactam; SXT, sulfamethoxazole/trimethoprim; ESBL, extended-spectrum β-lactamase; FAHZU, First Affiliated Hospital of Zhejiang University.

The results for Gram-positive pathogens showed that the ratio of MRSA ([Figure 1B](#F0001){ref-type="fig"}) decreased significantly from 2007 to 2016 (r=−0.769, *p*=0.009). However, the proportion of methicillin-resistant CNS remained unchanged ([Figure 1B](#F0001){ref-type="fig"}). During the study years, *S. aureus* and CNS became more sensitive to gentamicin, ciprofloxacin, erythromycin, clindamycin, and rifampicin ([Figure 1C](#F0001){ref-type="fig"}). The susceptibility in *E. faecium* was almost stable but increased to vancomycin (r=0.907, *p*=0.001) and gentamicin with a high concentration (r=0.921, *p*\<0.001). Different from that in *E. faecium*, the susceptibility in *E. faecalis* to different antibiotics improved remarkably ([Figure 1C](#F0001){ref-type="fig"}).

Trends of antibiotic consumption {#S0003-S2003}
--------------------------------

The overall antibiotic consumption decreased by 10.8% during the study period (r=−0.671, *p*=0.034). As shown in [Figure 2A](#F0002){ref-type="fig"}, consumption of first-generation cephalosporins (1GC, r=−0.882, *p*=0.001), fourth-generation cephalosporins (4GC, r=−0.762, *p*=0.010), aminoglycosides (r=−0.896, *p*\<0.001), and fluoroquinolones (r=−0.938, *p*\<0.001) fell by a wide margin, whereas the use of linezolid, carbapenems, glycopeptides, and third-generation cephalosporins (3GCs) grew substantially ([Figure 2B](#F0002){ref-type="fig"}), all increasing over 50%. A marked rise occurred after the introduction of linezolid in 2007, which was rarely used at the beginning, but the use grew from 0.13 DDD/1000-pd in 2007 to 14.64 DDD/1000-pd in 2016.Figure 2Trends of antibiotic consumption in FAHZU, 2007--2016 (**A**) and with the largest decreases in use (**B**).**Abbreviations:** GC, cephalosporin; 1GCs, first-generation cephalosporins; 3GC, third-generation cephalosporins; 4GCs, fourth-generation cephalosporins; FAHZU, First Affiliated Hospital of Zhejiang University.

Correlation between antibiotic susceptibility and consumption {#S0003-S2004}
-------------------------------------------------------------

The correlation between the consumption of these antibiotics with most significant changes ([Figure 2](#F0002){ref-type="fig"}) and the corresponding susceptibility is shown in [Tables 1](#T0001){ref-type="table"} and [2](#T0002){ref-type="table"}, respectively.Table 1Correlation between antibiotic consumption that decreased remarkably and the corresponding antibiotic susceptibilityPathogensAntibioticsTrend for susceptibilityCorrelation analysisr*p*TrendAntibiotic in consumptionr*p*Correlation*Klebsiella pneumoniae*Cefazolin−0.4570.362Stable1GCs0.4040.427No correlationCefepime0.7440.014Increasing4GCs−0.7630.010NegativeCiprofloxacin0.8330.003IncreasingFluoroquinolones−0.8490.002NegativeAmikacin0.6070.063StableGlycopeptides−0.6270.052No correlation*Escherichia coli*Cefazolin−0.0970.855Stable1GCs−0.3350.516No correlationCefepime0.9630.000Increasing4GCs−0.7630.010NegativeCiprofloxacin0.9530.000IncreasingFluoroquinolones−0.8570.002NegativeAmikacin0.9180.000IncreasingGlycopeptides−0.7840.007Negative*Acinetobacter baumannii*Cefepime−0.1100.762Stable4GCs0.1560.667No correlationCiprofloxacin0.7130.031IncreasingFluoroquinolones−0.7720.015NegativeAmikacin0.7490.013IncreasingGlycopeptides−0.8710.001Negative*Pseudomonas aeruginosa*Cefepime−0.1100.762Stable4GCs0.2190.543No correlationCiprofloxacin0.8000.005IncreasingFluoroquinolones−0.6470.043NegativeAmikacin0.8950.000IncreasingGlycopeptides−0.8610.001Negative*Staphylococcus aureus*Ciprofloxacin0.9150.000IncreasingFluoroquinolones−0.8670.001NegativeGentamicin0.902\<0.001IncreasingGlycopeptides−0.8180.004NegativeCoagulase- negative *staphylococcus*Ciprofloxacin0.8000.005IncreasingFluoroquinolones−0.6860.028NegativeGentamicin0.968\<0.001IncreasingGlycopeptides−0.886\<0.001Negative*Enterococcus faecium*Ciprofloxacin0.3940.260StableFluoroquinolones−0.5980.068No correlationGentamicin^a^0.921\<0.001IncreasingGlycopeptides−0.8270.003Negative*Enterococcus faecalis*Ciprofloxacin0.940\<0.001IncreasingFluoroquinolones−0.968\<0.001NegativeGentamicin^a^0.898\<0.001IncreasingGlycopeptides−0.8000.005Negative[^2] Table 2Correlation between antibiotic consumption that increased remarkably and the corresponding antibiotic susceptibilityPathogensAntibioticsTrend for susceptibilityCorrelation analysisr*p*TrendAntibiotic in consumptionr*p*Correlation*Escherichia coli*Imipenem0.0730.840StableCarbapenems−0.2160.549No correlationSCF−0.5300.115Stable3GCs/β-lactamase inhibitors^a^−0.6390.064No correlationCeftazidime0.6650.051Stable3GC sensitive to pae^b^0.4880.182No correlation*Klebsiella pneumoniae*Imipenem−0.6420.046DecreasingCarbapenems−0.6490.042NegativeSCF−0.7400.014Decreasing3GCs/β-lactamase inhibitors^a^−0.7080.033NegativeCeftazidime0.3470.360Stable3GC sensitive to pae^b^0.5110.160No correlation*Acinetobacter baumannii*Imipenem−0.0560.878StableCarbapenems0.0770.832No correlationSCF−0.7830.007Decreasing3GCs/β-lactamase inhibitors^a^−0.7750.014NegativeCeftazidime−0.2670.488Stable3GC sensitive to pae^b^−0.3220.398No correlation*Pseudomonas aeruginosa*Imipenem0.1670.644StableCarbapenems−0.0450.901No correlationSCF0.3870.269Stable3GCs/β-lactamase inhibitors^a^−0.0640.870No correlationCeftazidime−0.4880.152Stable3GC sensitive to pae^b^−0.4770.163No correlation*Staphylococcus aureus*Linezolid0.4100.274StableLinezolid0.2280.555No correlationVancomycinMaintained 100%Glycopeptides／／No correlationCoagulase-negative *staphylococcus*Linezolid−0.2750.473StableLinezolid−0.2810.464No correlationVancomycinMaintained 100%Glycopeptides／／No correlation*Enterococcus faecium*Linezolid−0.3200.401StableLinezolid0.0980.802No correlationVancomycin0.925\<0.001IncreasingGlycopeptides0.6330.049Positive*Enterococcus faecalis*Linezolid0.4830.188StableLinezolid0.1220.754No correlationVancomycin0.7350.015IncreasingGlycopeptides0.7520.012Positive[^3]

For 1GCs, 4GCs, fluoroquinolones, and aminoglycosides, 16 of the total 22 (72.7%) trend analyses suggested increasing susceptibility, which was well correlated with the decreased consumption of the corresponding antibiotics ([Table 1](#T0001){ref-type="table"}). In particular, susceptibility to aminoglycosides and fluoroquinolones rose markedly in seven of eight pathogens and was negatively related to the corresponding antibiotic consumption. However, the susceptibility of different pathogens to 1GCs remained unchanged. The correlation between consumption and susceptibility to antibiotics with increased consumption was not as remarkable as those with decreased consumption. As shown in [Table 2](#T0002){ref-type="table"}, only 4 of 12 (25%) trend analyses indicated decreasing susceptibility in Gram-negative pathogens to those with increased consumption. In terms of Gram-positive pathogens, the consumption of glycopeptides even positively correlated with the growing susceptibility to vancomycin in *E. faecium* (r=0.633, *p*=0.049) and *E. faecalis* (r=0.752, *p*=0.012).

Considering that the isolations of ESBL-producing pathogens and MRSA varied significantly (*p*\<0.5), we conducted a correlation analysis to investigate the factors behind these variations. As shown in [Table 3](#T0003){ref-type="table"}, the isolation density of ESBL-producing *E. coli* negatively correlated with the consumption of carbapenems and cephalosporins/β-lactamase inhibitors. The isolation density of ESBL-producing *K. pneumoniae* was positively related to the use of fluoroquinolones but not correlated with the use of either carbapenems or cephalosporins/β-lactamase inhibitors. As for MRSA, the isolation density negatively correlated with the use of fluoroquinolones but not with other antibiotics.Table 3Correlation between isolations of important pathogens (ESBL-producing *Enterobacteriaceae* and MRSA) and antibiotic consumptionPathogensTrend for susceptibilityCorrelation analysisr*p*TrendAntibiotic in consumptionr*p*Correlation*Escherichia coli*ESBL−0.7450.013Decreasing3GCs0.2700.452No correlationPCs with extended spectrum0.4300.215No correlationCarbapenems−0.8770.001NegativeCephalosporins/β-lactamase inhibitors−0.7300.017NegativeFluoroquinolones0.5450.104No correlation*Klebsiella pneumoniae*ESBL−0.7890.007Decreasing3GCs−0.1340.712No correlationPCs with extended spectrum−0.5760.081No correlationCarbapenems0.1360.708No correlationCephalosporins/β-lactamase inhibitors−0.5210.123No correlationFluoroquinolones0.8650.001Positive*Staphylococcus aureus*MRSA−0.7670.009DecreasingPenicillins0.6150.059No correlationCephalosporins0.1980.584No correlationβ-lactamase antibiotics0.2330.518No correlationCarbapenems−0.5240.120No correlationFluoroquinolones0.7810.008PositiveGlycopeptides−0.1420.695No correlation[^4]

Discussion {#S0004}
==========

The drug resistance status between People's Republic of China and some developed counties had a wide gap.[@CIT0005],[@CIT0006],[@CIT0010],[@CIT0018],[@CIT0020] To improve the serious situation, Chinese government launched a series of policies and guidelines. As one of the best and largest comprehensive hospitals in People's Republic of China, FAHZU has also implemented multifaceted interventions and measures. Several improvements were observed, including the following: 1) the overall antibiotic consumption decreased; 2) susceptibility markedly rose to many antibiotics in different pathogens; 3) isolation density of serious drug-resistant pathogens, such as MRSA and ESBL-producing isolates, remarkably declined and the well control of fluoroquinolones possibly contribute to these improvements.

The current result confirms that proper management of antibiotics can decelerate or even reverse bacterial resistance. The most successful example was that seven of eight (87.5%) investigated pathogens became more sensitive to both aminoglycosides and fluoroquinolones, which well correlated with the corresponding drug consumption. At present, these antibiotics have become an option against CRE and many other multidrug-resistant pathogens.[@CIT0021],[@CIT0022] Thus, discontinuing or strictly controlling antibiotics with a high resistance rate for a certain period, similar to the "fallow cropping system", can be considered an effective way to reduce the selection pressure from antibiotics.[@CIT0023],[@CIT0024] The results also demonstrated the development of resistance against antibiotics seems considerably slower than the recovery rate of susceptibility, given that 72.7% trend analyses suggested increasing susceptibility in antibiotics with remarkably decreased consumption, whereas only 15.0% trend analyses indicated declined susceptibility in antibiotics with increased consumption during the study time, strengthening our confidence to improve the usage of antibiotics.

The isolation density of MRSA was decreased with time and positively correlated with the consumption of fluoroquinolones, which are also recognized as the risk factor for MRSA in previous studies.[@CIT0025],[@CIT0026] Given that fluoroquinolones may also contribute to the prevalence of ESBL-producing pathogens in FAHZU and in other settings,[@CIT0027] strict control of the use of fluoroquinolones should be insisted on in the future. The susceptibility of *E. faecium* and *E. faecalis* to vancomycin increased but positively correlated with its consumption. One possible explanation is that with more experience to use vancomycin, such as PK/PD thesis and therapeutic drug monitoring,[@CIT0028],[@CIT0029] the concentration of vancomycin could exceed the mutant prevention concentration, thereby decreasing the prevalence of resistance.[@CIT0028]--[@CIT0030] In fact, the isolation density of vancomycin-resistant *E. faecium* and *E. faecalis* were 0% and 0.5%, respectively, in our hospital in 2016, which are lower than the national level (0.4% in *E. faecium* and 1.9% in *E. faecalis*), and less than that in many counties worldwide.[@CIT0002],[@CIT0031] This result illuminates that developing a comprehensive strategy that not only limits the consumption but also involves administering the proper dose, duration, and time to use antibiotics is necessary.[@CIT0032]

However, some shortcomings still existed. Firstly, the susceptibility to carbapenems in *K. pneumoniae* decreased. In our study, the correlation analysis indicated that the increasing consumption of carbapenems may contribute to the burden of carbapenem-resistant *K. pneumoniae* (CRKP). The effect from carbapenems on the resistance of *K. pneumonia* was also found in other studies both in People's Republic of China and worldwide.[@CIT0003],[@CIT0004],[@CIT0011],[@CIT0021],[@CIT0033] Other risk factors that related with CRKP were invasive mechanical ventilation, parenteral nutrition, high APACHE II score, and so on.[@CIT0034],[@CIT0035] As a tertiary-care teaching hospital, the number of hospitalizations in the FAHZU increased markedly, and many critical patients who were easily exposure to CRKP-related factors would be transferred to the FAHZU from other hospitals (such as secondary-care teaching hospitals), therefore may result in the increasing trends of CRKP.[@CIT0033] The epidemics of CRE have gradually been challenging worldwide.[@CIT0001],[@CIT0002],[@CIT0036] In Europe, the resistance to carbapenem in *K. pneumoniae* increased in 5 of 24 countries from 2009 to 2012.[@CIT0037] However, the CRE isolation density in some countries retained a low level. For example, the CRE isolation density in Germany was 0% from 2011 to 2013 and was \<6% in Egypt from 2002 to 2010.[@CIT0006] Therefore, opportunities are available to control the prevalence of CRE. The strict management of carbapenems has been included in the latest strategy in our hospital, introducing pharmacy consultation before prescribing carbapenems. Another limitation was that the lack of epidemiological analyses and subsequent data, such as the circulation of a clone of ESBL-producing *E. coli* with patients' cross infections, may affect the statistical significance. Finally, the correlation between antibiotics and consumption is well displayed but cannot confirm causal relationship due to the study design. However, this study was based on 10-year data from 63,711 isolated pathogens in a large comprehensive hospital, covering the most important pathogens in hospital-acquired infections and a full range of antibiotics that are frequently used worldwide. Therefore, the results can illuminate ways to combat drug resistance in other hospitals with a similar situation.

Conclusion {#S0005}
==========

With the multifaceted interventions to improve the appropriate use of antibiotics and combat antibiotic resistance, the susceptibility of different pathogens to many antibiotics considerably increased. Despite the improvements, the decreasing trend of carbapenem-sensitive *Enterobacteriaceae* necessitates the strict management of carbapenems.
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